Replies to post #61490 on Biotech Values

[zipjet]

>>whether the control was adequate

It was not a controlled study.

>>Also, judging from market's rxn to Tysabrio news (ELN up 11% today), the market didn't think it was a big deal either.

GS also upgraded ELN today target 32 (think I saw that). GS did note the PML risk.

ij